CSL News: Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm - 23rd Feb 2024, 11:05pm

You must log in or register to reply here.

Similar threads

annb0t
CSL News: Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) f - 24th Apr 2024, 9:05pm
Replies
0
Views
48
annb0t
annb0t
annb0t
CSL News: CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) f - 24th Apr 2024, 5:00pm
Replies
0
Views
28
annb0t
annb0t
annb0t
CSL News: Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Au - 22nd Aug 2022, 9:00pm
Replies
0
Views
149
annb0t
annb0t
annb0t
CSL News: Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder - 22nd Aug 2022, 11:58pm
Replies
0
Views
142
annb0t
annb0t
annb0t
CSL News: ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization - 30th Apr 2024, 11:01pm
Replies
0
Views
47
annb0t
annb0t
Top Bottom